Acute lymphoblastic leukemia: older patients and newer drugs.
Although the median age for adults with acute lymphoblastic leukemia (ALL) is older than 60 years, relatively few of these patients have been enrolled on prospective clinical trials. The presence of coexisting medical disorders and unfavorable cytogenetic and biological characteristics within this population presents considerable challenges for successful treatment using conventional chemotherapy programs. Selected patients have achieved remission and long-term survival following intensive chemotherapy. Preliminary data using several new agents that have shown promise for patients with ALL are described.
Larson
Richard A
RA
Department of Medicine and the Cancer Research Center, University of Chicago, Chicago, IL 60637, USA. rlarson@medicine.bsd.uchicago.edu
D000293:Adolescent; D000328:Adult; D017677:Age Distribution; D000368:Aged; D000369:Aged, 80 and over; D002648:Child; D002880:Chromosomes, Human, Pair 11; D005260:Female; D015321:Gene Rearrangement; D006801:Humans; D008297:Male; D008875:Middle Aged; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000453:epidemiology* / Q000235:genetics; D055815:Young Adult